Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 12/20 | 0.42 |
| ▸ | CCKAR | P32238 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOTCH1 | P46531 | 5/20 | 0.39 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.39 |
| ▸ | NOTCH3 | Q9UM47 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440665 | 0.81 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL22440667 | 0.81 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL22440664 | 0.74 | CCKBR (0.49) | CCKBRCCKARMEN1ALDH1A1KMT2A | |
| SCHEMBL22460069 | 0.74 | CCKBR (0.51) | CCKBRCCKARNOTCH1NOTCH3 | |
| SCHEMBL18394376 | 0.74 | CBLB (0.47) | CCKBRCCKAR | |
| SCHEMBL20474810 | 0.72 | CCKAR (0.44) | CCKBRCCKARALDH1A1 | |
| SCHEMBL22459538 | 0.71 | CCKBR (0.44) | CCKBRCCKARNOTCH1RBPJNOTCH3 | |
| SCHEMBL22440644 | 0.71 | CCKBR (0.43) | CCKBRCCKARMEN1ALDH1A1KMT2A | |
| SCHEMBL22440654 | 0.70 | P2RX7 (0.45) | ALDH1A1 | |
| SCHEMBL18395704 | 0.68 | CBLB (0.45) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360117-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220227746-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3941525-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-09-24 | — | — | US | disclosed |
| WO-2020190935-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885MEN1 3463/4885 |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885MEN1 3463/4885 |
| US-20240360117-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885MEN1 3463/4885 |
| US-20220227746-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885MEN1 3463/4885 |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885MEN1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.